<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01922024</url>
  </required_header>
  <id_info>
    <org_study_id>CURETIS LRT55 Study - V 6.0</org_study_id>
    <nct_id>NCT01922024</nct_id>
  </id_info>
  <brief_title>Detection of Microorganisms and Antibiotic Resistance Genes Using the Curetis Unyvero LRT55 Application</brief_title>
  <acronym>LRT55</acronym>
  <official_title>Detection of Microorganisms and Antibiotic Resistance Genes in Lower Respiratory Tract (LRT) Samples Using the Curetis Unyvero LRT55 Application</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Curetis GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Global BioClinical</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Curetis GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Curetis Unyvero LRT55 Application is intended to detect and to identify genes of 21
      microorganisms and 19 genes associated with antibiotic resistance in 4 hours.

      In this study, the performance of the Unyvero LRT55 Application shall be tested under
      clinical conditions and compared to (1) a composite reference method (for non-atypical or
      cultured microorganisms) or (2) a molecular PCR based reference method for the 3 atypical
      microorganisms Chlamydophila pneumoniae, Legionella pneumoniae, and Pneumocystis jirovecii,
      and for resistance genes.

      PCR amplifications are followed by bi-directional sequencing, including comparison of the
      test results Time to result will be compared for the Unyvero LRT55 Application and
      standard-of care.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a non-interventional, controlled, non-randomized multicenter clinical study that
      compares a new diagnostic device, the Unyvero LRT55 Application (based on molecular
      diagnostic methods) to either (1) a composite reference method (for non-atypical
      microorganisms), (2) a composite PCR-based method for 3 atypical microorganisms or (3) a
      PCR-based reference method for resistance genes.

      The study will use leftover lower respiratory tract samples taken from subjects suspected
      with lower respiratory tract infections: (a) Specimens taken prospectively for
      standard-of-care (i.e. microbiology testing) from hospitalized subjects. (b) Banked specimens
      for rare microorganisms.

      As the device is under investigation, the test results provided by the Unyvero LRT55
      Application will not be made available to the treating physician and therefore will not be
      used for diagnosis, treatment or other management decisions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Sensitivity and Specificity for Microorganism Detection as Compared to Routine Microbiology and Other Reference Methods Including PCR and Sequencing</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Sensitivity for microorganism detection will be determined against the respective reference method consisting of standard procedure and/or a reference method based on PCR and bi-directional sequencing using alternative primers. Sensitivity for non-atypical microorganism detection will thus be determined if at least 1 out of 2 reference methods have identified microorganisms that are covered by the panel of the investigational IVD. Results will further be analyzed against standard of-care alone, as well as against composite comparator. Sensitivity for atypical microorganism detection will be determined against PCR with alternative primers as reference method. Specificity for microorganism detection will be determined in all samples included in the trial. Individual specificities will be calculated for the detection of the respiratory microorganisms analyzed by the investigational IVD compared to the microorganisms reference method.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">2124</enrollment>
  <condition>Pneumonia</condition>
  <arm_group>
    <arm_group_label>Prospective Fresh Clinical Specimens</arm_group_label>
    <description>Patients with suspicion of lower respiratory tract infection (pneumonia), samples tested with Unyvero LRT 55 cartridge and results compared against composite (comparator) which is based on routine clinical microbiology and a second PCR test</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Retrospective Frozen Clinical Specimens</arm_group_label>
    <description>Patients with suspicion of lower respiratory tract infection (pneumonia), samples tested with Unyvero LRT 55 cartridge and results compared against routine clinical microbiology</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>LRT55 Testing</intervention_name>
    <description>Testing on the Unyvero LRT55</description>
    <arm_group_label>Prospective Fresh Clinical Specimens</arm_group_label>
    <arm_group_label>Retrospective Frozen Clinical Specimens</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Bronchial lavage (BAL) Tracheal aspirate (TA)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Suspicion of lower respiratory tract infection in hospitalized subjects.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hospitalized subjects with suspicion of lower respiratory tract infection

          -  Age at least 18 years

          -  Available surplus respiratory aspirate or bronchial lavage sample

        Exclusion Criteria:

          -  Out-patient (ambulatory patient)

          -  Known infection with HIV, HBV or tuberculosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johannes Bacher</last_name>
    <role>Study Director</role>
    <affiliation>Curetis GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California Los Angeles (UCLA)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90049</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>William Beaumont Hospital</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia Universiy Medical Center / New York-Presbyterian Hosp.</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Summa Health System</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>August 7, 2013</study_first_submitted>
  <study_first_submitted_qc>August 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 14, 2013</study_first_posted>
  <results_first_submitted>January 25, 2017</results_first_submitted>
  <results_first_submitted_qc>February 28, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">March 5, 2019</results_first_posted>
  <last_update_submitted>February 28, 2019</last_update_submitted>
  <last_update_submitted_qc>February 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Prospective Fresh Clinical Specimens</title>
          <description>Patients with suspicion of lower respiratory tract infection (pneumonia), samples tested with Unyvero LRT 55 cartridge and results compared against composite (comparator) which is based on routine clinical microbiology and a second PCR test
LRT55 Testing: Testing on the Unyvero LRT55</description>
        </group>
        <group group_id="P2">
          <title>Retrospective Frozen Clinical Specimens</title>
          <description>Patients with suspicion of lower respiratory tract infection (pneumonia), samples tested with Unyvero LRT 55 cartridge and results compared against routine clinical microbiology
LRT55 Testing: Testing on the Unyvero LRT55</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1653"/>
                <participants group_id="P2" count="471"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1653"/>
                <participants group_id="P2" count="471"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Prospective Fresh Clinical Specimens</title>
          <description>Patients with suspicion of lower respiratory tract infection (pneumonia), samples tested with Unyvero LRT 55 cartridge and results compared against composite (comparator) which is based on routine clinical microbiology and a second PCR test
LRT55 Testing: Testing on the Unyvero LRT55</description>
        </group>
        <group group_id="B2">
          <title>Retrospective Frozen Clinical Specimens</title>
          <description>Patients with suspicion of lower respiratory tract infection (pneumonia), samples tested with Unyvero LRT 55 cartridge and results compared against routine clinical microbiology
LRT55 Testing: Testing on the Unyvero LRT55</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1653"/>
            <count group_id="B2" value="471"/>
            <count group_id="B3" value="2124"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="827"/>
                    <measurement group_id="B2" value="186"/>
                    <measurement group_id="B3" value="1013"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="826"/>
                    <measurement group_id="B2" value="285"/>
                    <measurement group_id="B3" value="1111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="665"/>
                    <measurement group_id="B2" value="182"/>
                    <measurement group_id="B3" value="847"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="988"/>
                    <measurement group_id="B2" value="289"/>
                    <measurement group_id="B3" value="1277"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1653"/>
                    <measurement group_id="B2" value="471"/>
                    <measurement group_id="B3" value="2124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clinical Sensitivity and Specificity for Microorganism Detection as Compared to Routine Microbiology and Other Reference Methods Including PCR and Sequencing</title>
        <description>Sensitivity for microorganism detection will be determined against the respective reference method consisting of standard procedure and/or a reference method based on PCR and bi-directional sequencing using alternative primers. Sensitivity for non-atypical microorganism detection will thus be determined if at least 1 out of 2 reference methods have identified microorganisms that are covered by the panel of the investigational IVD. Results will further be analyzed against standard of-care alone, as well as against composite comparator. Sensitivity for atypical microorganism detection will be determined against PCR with alternative primers as reference method. Specificity for microorganism detection will be determined in all samples included in the trial. Individual specificities will be calculated for the detection of the respiratory microorganisms analyzed by the investigational IVD compared to the microorganisms reference method.</description>
        <time_frame>Up to 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prospective Fresh Clinical Specimens</title>
            <description>Patients with suspicion of lower respiratory tract infection (pneumonia), samples tested with Unyvero LRT 55 cartridge and results compared against composite (comparator) which is based on routine clinical microbiology and a second PCR test
LRT55 Testing: Testing on the Unyvero LRT55
an overall weighted average sensitivity of 91.4% for detection of panel pathogens an overall weighted average specificity of 99.5% for detection of panel pathogens
an overall weighted average sensitivity of 89.9 % for detection of resistance markers an overall weighted average specificity of 99.3 % for detection of resistance markers</description>
          </group>
          <group group_id="O2">
            <title>Retrospective Frozen Clinical Specimens</title>
            <description>Patients with suspicion of lower respiratory tract infection (pneumonia), samples tested with Unyvero LRT 55 cartridge and results compared against routine clinical microbiology
LRT55 Testing: Testing on the Unyvero LRT55
an overall weighted average sensitivity of 91.4% for detection of panel pathogens an overall weighted average specificity of 99.5% for detection of panel pathogens
an overall weighted average sensitivity of 89.9 % for detection of resistance markers an overall weighted average specificity of 99.3 % for detection of resistance markers</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Sensitivity and Specificity for Microorganism Detection as Compared to Routine Microbiology and Other Reference Methods Including PCR and Sequencing</title>
          <description>Sensitivity for microorganism detection will be determined against the respective reference method consisting of standard procedure and/or a reference method based on PCR and bi-directional sequencing using alternative primers. Sensitivity for non-atypical microorganism detection will thus be determined if at least 1 out of 2 reference methods have identified microorganisms that are covered by the panel of the investigational IVD. Results will further be analyzed against standard of-care alone, as well as against composite comparator. Sensitivity for atypical microorganism detection will be determined against PCR with alternative primers as reference method. Specificity for microorganism detection will be determined in all samples included in the trial. Individual specificities will be calculated for the detection of the respiratory microorganisms analyzed by the investigational IVD compared to the microorganisms reference method.</description>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1653"/>
                <count group_id="O2" value="471"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sensitivity - Pathogen Detection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.4" lower_limit="91.4" upper_limit="91.4"/>
                    <measurement group_id="O2" value="91.4" lower_limit="91.4" upper_limit="91.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Specificity- Pathogen Detection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.5" lower_limit="99.5" upper_limit="99.5"/>
                    <measurement group_id="O2" value="99.5" lower_limit="99.5" upper_limit="99.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sensitivity - Restistance Marker Detection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.9" lower_limit="89.9" upper_limit="89.9"/>
                    <measurement group_id="O2" value="89.9" lower_limit="89.9" upper_limit="89.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Specificity - Resistance Marker Detection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.3" lower_limit="99.3" upper_limit="99.3"/>
                    <measurement group_id="O2" value="99.3" lower_limit="99.3" upper_limit="99.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>There were no adverse events monitored or occurring in this study, because this study utilized remnant human biospecimens that had previously been collected for clinical diagnosis not related to the study. All specimens and study testing results were de-identified and had not impact on patient care or treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Prospective Fresh Clinical Specimens</title>
          <description>Patients with suspicion of lower respiratory tract infection (pneumonia), samples tested with Unyvero LRT 55 cartridge and results compared against composite (comparator) which is based on routine clinical microbiology and a second PCR test
LRT55 Testing: Testing on the Unyvero LRT55</description>
        </group>
        <group group_id="E2">
          <title>Retrospective Frozen Clinical Specimens</title>
          <description>Patients with suspicion of lower respiratory tract infection (pneumonia), samples tested with Unyvero LRT 55 cartridge and results compared against routine clinical microbiology
LRT55 Testing: Testing on the Unyvero LRT55</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Operations</name_or_title>
      <organization>Curetis USA, Inc.</organization>
      <phone>800-659-1221</phone>
      <email>neil.mucci@curetis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

